Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 in previously treated malignant pleural mesothelioma
ACTRN12615001291572Phase 2Terminated
- Sponsor
- Institute for Respiratory Health
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fexagratinib in pleural mesothelioma, sponsored by Institute for Respiratory Health. Primary endpoint: Progression-free survival at 6 months. Started Apr 2016; status: terminated.
02
Drugs
fexagratinib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ACTRN12615001291572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001291572.